GW Pharmaceuticals plc (NASDAQ:GWPH, LON:GWP) cannabinoid drug Epidiolex has achieved primary endpoint in treating Lennox-Gastaut syndrome - a severe form of childhood epilepsy - speeding through phase three trials.
Back in June, the group’s first pivotal phase three study of Epidiolex for the treatment of seizures in connection with the syndrome revealed favourable results. And then in March, the group released positive results in connection with Dravet syndrome.
Epidiolex was well tolerated during the trial period. The adverse pattern of events was in line with the previously reported two Phase 3 studies.
GW Pharmaceuticals expects to file a new drug application to the FDA in the first half of next year.
"We feel a tremendous sense of urgency to stop seizures, and believe that the pursuit of new therapies offers hope to individuals who have no currently available therapy to effectively stop their seizures,” said chief executive Philip Gattone.
Shares trading on the London Stock Exchange rose 11% to 775.5p.